Lakewood Asset Management’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$871K Buy
3,564
+3
+0.1% +$699 0.56% 44
2025
Q4
$737K Buy
3,561
+3
+0.1% +$593 0.43% 51
2025
Q3
$660K Buy
3,558
+4
+0.1% +$685 0.4% 55
2025
Q2
$543K Sell
3,554
-71
-2% -$10.9K 0.36% 60
2025
Q1
$601K Sell
3,625
-2,228
-38% -$349K 0.41% 52
2024
Q4
$847K Buy
5,853
+4
+0.1% +$620 0.58% 47
2024
Q3
$948K Sell
5,849
-129
-2% -$20.6K 0.65% 42
2024
Q2
$874K Sell
5,978
-797
-12% -$119K 0.61% 42
2024
Q1
$1.07M Buy
6,775
+606
+10% +$96.5K 0.73% 41
2023
Q4
$967K Sell
6,169
-546
-8% -$83.7K 0.75% 39
2023
Q3
$1.05M Sell
6,715
-393
-6% -$64.8K 0.85% 38
2023
Q2
$1.18M Buy
7,108
+116
+2% +$18.7K 0.93% 36
2023
Q1
$1.08M Buy
6,992
+83
+1% +$13.4K 0.9% 38
2022
Q4
$1.22M Buy
+6,909
New +$1.19M 0.99% 29

Other funds holding JNJ

Lakewood Asset Management's JNJ Position: Q1 2026 in Review

Lakewood Asset Management increased its Johnson & Johnson (JNJ) stake by 0.08% in Q1 2026, buying an estimated $699 and bringing the position to 3,564 shares worth $871K. The position accounts for 0.56% of the portfolio, ranked #44.

Lakewood Asset Management first reported a position in JNJ in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.22M in Q4 2022. 4,616 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Lakewood Asset Management held 3,564 shares of Johnson & Johnson worth $871K as of Q1 2026.
  • Lakewood Asset Management bought 3 Johnson & Johnson shares in Q1 2026, an estimated $699.
  • Johnson & Johnson made up 0.56% of Lakewood Asset Management's portfolio in Q1 2026, its #44 holding.
  • Lakewood Asset Management first reported a position in Johnson & Johnson in Q4 2022 and has held it in 14 quarters since.
  • Lakewood Asset Management's Johnson & Johnson position peaked at $1.22M in Q4 2022.
  • 4,616 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Lakewood Asset Management's 13F filing for Q1 2026, filed 23 Apr 2026.